The 31 references in paper M. Mamedov N., М. Kolchina A., М. Мамедов А., М. Колчина А. (2018) “ПРИМЕНЕНИЕ ПИТАВАСТАТИНА ПРИ САХАРНОМ ДИАБЕТЕ 2 ТИПА И ВЫСОКОМ СЕРДЕЧНО-СОСУДИСТОМ РИСКЕ: КЛИНИЧЕСКИЙ ПРИМЕР // EVALUATING THE USE OF PITAVASTATIN IN TYPE 2 DIABETES MELLITUS AND HIGH CARDIOVASCULAR RISK: CLINICAL CASE” / spz:neicon:aterotromboz:y:2018:i:1:p:132-139

1
Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C,Wood DA, Zamorano JL; Authors/Task Force Members; Additional Contributor.
(check this in PDF content)
2
16 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J, 2016, 37(39): 2999-3058. 2016 ESC/EAS guidelines for the management of dysli pidaemias. 2. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WM, Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Deve
(check this in PDF content)
3
29): 2315-2381. 3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ, 2003, 326(7404): 1419.
(check this in PDF content)
4
The Federal Service of State Statistics. Russian (Федеральная служба государственной статистики). www.gks.ru.
(check this in PDF content)
5
Muromtseva GA, Kontsevaya AV, Konstantinov VV, Artamonova GV, Gatagonova TM, Duplyakov DV, Efanov AY, Zhernakova YV, Il’n VA, Konradi AO, Libis RA, Minakov EV, Nedogoda SV, Oschepkova EV, Romanchuk SV, Rotar OP, Trubacheva IA, Deev AD, Shalnova SA, Chazova IE, Shlyakhto EV, Boytsov SA. The prevalence of non-infectious diseases risk factors in Russian population in 20122013 years. The results of ECVD-RF. Cardiovascular Therapy and Prevention. 2014, 13(6): 4-11./Распространенность факторов риска хронических неинфекционных заболеваний в российской популяции в 2012-2013 годах. Результаты исследования ЭССЭ-РФ. КВТиП, 2014, 13(6): 4-11).
(check this in PDF content)
6
Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract, 2005, 59(2): 239-252.
(check this in PDF content)
7
Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther, 2006, 80: 565-581.
(check this in PDF content)
8
Saito Y. Pitavastatin: An overview. Atheroscler Suppl, 2011 Nov, 12(3): 271-276.
(check this in PDF content)
9
Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica, 2004, 34: 961-971.
(check this in PDF content)
10
Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet, 2008, 47: 463-474.
(check this in PDF content)
11
Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics, 2007, 8: 787-802.
(check this in PDF content)
12
Hounslow N. Pitavastatin has a low risk of drug-drug interactions: pharmacokinetic studies in combination with modulators of CYP450 and OATP. Presented at XVII International Symposium on Drugs Affecting Lipid Metabolism. Diabetes, Obesity, and the Metabolic Syndrome. Doha, Qatar, March 14-16, 2011.
(check this in PDF content)
13
Ramkumar S, Raghunath А Raghunath S. Statin Therapy: Review of Safety and Potential Side Effects. Acta Cardiol Sin, 2016, 32: 631-639.
(check this in PDF content)
14
Pelliccia F, Rosano G, Marazzi G, Vitale C, Spoletini I, Franzoni F, Speziale G, Polacco M, Greco C, Gaudio C. Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual anti platelet therapy. Circ J, 2014, 78(3): 679-684.
(check this in PDF content)
15
Saku K, Zhang B, Noda K. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL)-The PATROL trial. Circ J, 2011, 75(6): 1493-1505.
(check this in PDF content)
16
Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S. A 52-week, randomized, open-label, parallelgroup comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density li poprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density li poprotein cholesterol and glucose intolerance. Clin Ther, 2008, 30(6): 1089-1101.
(check this in PDF content)
17
Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dysli pidemia. Clin Lipidol, 2009, 4(3): 291-302.
(check this in PDF content)
18
Ose L, Budinski D, Hounslow N, Arneson V. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis, 2010, 210(1): 202-208.
(check this in PDF content)
19
Yokote K, Bujo H, Hanaoka H, Shinomiya M, Mikami K, Miyashita Y, Nishikawa T, Kodama T, Tada N, Saito Y. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis, 2008, 201(2): 345-352.
(check this in PDF content)
20
Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther, 2010, 35(2): 139-151.
(check this in PDF content)
21
Fukutomi T, Takeda Y, Suzuki S, Ito T, Joh T, Itoh M. High density li poprotein cholesterol and apoli poprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor. Int J Cardiol, 2010, 141: 320-322.
(check this in PDF content)
22
Kakuda H, Kobayashi J, Nakato M, Takekoshi N. Shortterm effect of pitavastatin treatment on glucose and lipid metabolism and oxidative stress in fasting and postprandial state using a test meal in Japanese men. Cholesterol, 2013, 2013: 314170.
(check this in PDF content)
23
Koshiyama H, Taniguchi A, Tanaka K, Kagimoto S, Fujioka Y, Hirata K, Nakamura Y, Iwakura A, Hara K, Yamamoto T, Kuroe A, Ohya M, Fujimoto S, Hamamoto Y, Honjo S, Ikeda H, Nabe K, Tsuda K, Inagaki N, Seino Y, Kume N, Kansai Investigation of Statin for Hyperli pidemic Intervention in Metabolism and Endocrinology Investigators. Effects of pitavastatin on li pid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperli pidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars. J Atheroscler Thromb, 2008, 15(6): 345-350.
(check this in PDF content)
24
Miller PE, Martin SS, Joshi PH, Jones SR, Massaro JM, D’gostino RB, Sponseller CA, Toth PP. Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Li poprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperli pidemia or Mixed Dysli pidemia. Clin Ther, 2016, 38(3): 603-609.
(check this in PDF content)
25
Braamskamp MJ, Stefanutti C, Langslet G, Drogari E, Wiegman A, Hounslow N, Kastelein JJ, PASCAL Study Group. Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk. J Pediatr, 2015 Aug, 167(2): 338-343.
(check this in PDF content)
26
Harada-Shiba M, Arisaka O, Ohtake A, Okada T, Suganami H, NK-104-PH 01 study registration group. Efficacy and Safety of Pitavastatin in Japanese Male Children with Familial Hypercholesterolemia. J Atheroscler Thromb, 2016, 23(1): 48-55.
(check this in PDF content)
27
Saito Y. Critical appraisal of the role of pitavastatin in treating dysli pidemias and achieving li pid goals. Vasc Health Risk Manag, 2009, 5: 921-936.
(check this in PDF content)
28
Kodama K, Komatsu S, Ueda Y, Takayama T, Yajima J, Nanto S, Matsuoka H, Saito S, Hirayama A. Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound – the TOGETHAR trial. Circ J, 2010, 74(9): 1922-1928.
(check this in PDF content)
29
Feng T, Huang X, Liang Q, Liang Y, Yuan Y, Feng L, Wu W, Xiao X, Han Y. Effects of Pitavastatin on Lipid-rich Carotid Plaques Studied Using High-resolution Magnetic Resonance Imaging. Clin Ther, 2017 Mar, 39(3): 620-629.
(check this in PDF content)
30
Davignon J. Pleiotropic effects of pitavastatin. Br J Clin Pharmacol, 2012, 73: 518-535.
(check this in PDF content)
31
Eriksson M, Budinski D, Hounslow N. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. Adv Ther, 2011 Sep, 28(9): 811-823.
(check this in PDF content)